Dose-range Finding Efficacy and Safety Study for QBW251 in COPD Patients

Inclusion Criteria:

Male and female COPD patients aged ≥40 years, who have signed an Informed Consent Form prior to initiation of any study-related procedure.
Current or ex-smokers who have a smoking history of at least 10 pack years.
Patients who have been treated with a triple combination of LABA/LAMA/ICS for the last 3 months prior to screening.
Patients featuring chronic bronchitis

Exclusion Criteria:

Patients who have had a COPD exacerbation that required treatment with antibiotics and/or oral corticosteroids and/or hospitalization, or a respiratory tract infection in the 4 weeks prior to screening, or between screening and randomization.
Patients with any documented history of asthma, or with an onset of chronic respiratory symptoms, including a COPD diagnosis, prior to age 40 years.
Patients with a body mass index (BMI) of more than 40 kg/m2.
Use of other investigational drugs (approved or unapproved) within 30 days or 5 half-lives prior to screening, or until the expected pharmacodynamic effect has returned to baseline (e.g., biologics), whichever is longer; or longer if required by local regulations.
Pregnant or nursing (lactating) women, and women of childbearing potential not willing to use acceptable effective methods of contraception during study participation.
Other protocol-defined inclusion/exclusion criteria may apply